Asahi Kasei Corp 2025 IR
The report outlines Asahi Kasei's progress in its business portfolio transformation and the launch of its new medium-term management plan, "Trailblaze Together," for fiscal 2025–2027. The company achieved record-high operating income of ¥211.9 billion in fiscal 2024, driven by growth in its Healthcare and Homes sectors. Key highlights include the acquisition of Calliditas Therapeutics to expand its global pharmaceuticals business and the construction of an integrated lithium-ion battery separator plant in Canada. Additionally, the company made significant progress toward carbon neutrality, reducing its Scope 1 and 2 greenhouse gas emissions by 38% compared to fiscal 2013.
Company: Asahi Kasei Corp
Sector: Materials
Country: Japan
Year: 2025
Type: IR
Pages: 107
Asahi Kasei Corp
Corporate Report
The report outlines Asahi Kasei's progress in its business portfolio transformation and the launch of its new medium-term management plan, "Trailblaze Together," for fiscal 2025–2027. The company achieved record-high operating income of ¥211.9 billion in fiscal 2024, driven by growth in its Healthcare and Homes sectors. Key highlights include the acquisition of Calliditas Therapeutics to expand its global pharmaceuticals business and the construction of an integrated lithium-ion battery separator plant in Canada. Additionally, the company made significant progress toward carbon neutrality, reducing its Scope 1 and 2 greenhouse gas emissions by 38% compared to fiscal 2013.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Net Zero Target
Employees